Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.33 USD
+0.30 (9.90%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.33 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Cellectar Biosciences, Inc. [CLRB]
Reports for Purchase
Showing records 81 - 100 ( 123 total )
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
3Q20: Looking Forward to Pivotal Trial Initiation for CLR 131 in LPL/WM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Interim Phase 1 Results Show CLR 131''s Activity in Pediatric Brain Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Consistently Robust Phase 2 CLR 131 Data in Triple-Class Refractory MM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
CLR 131 Detailed Phase 2a Data at AACR, Deep - Durable Response in LPL/WM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
2Q20: Over a Year of Cash Runway, Looking Forward to 2H20 Data Releases
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Catching Up with Management - Approaching Pivotal CLR 131 Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Pivotal Study Schedule Intact Despite the Pandemic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
No COVID-19 Clinical Trial Slowdowns, Cash Runway Into 1Q21, Reports 1Q20
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Undervalued in the Face of Robust Efficacy - Reports 4Q19, Cash Into 1Q21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J